Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    evonik-m-2025-09-08

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Menu

    Lorundrostat

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 247,857Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Mineralys Reveals Ph3 Efficacy of Lorundrostat in Hypertension
    Mineralys Reveals Ph3 Efficacy of Lorundrostat in Hypertension

    05 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/05/3145274/0/en/Mineralys-Therapeutics-Presents-Subgroup-Analyses-of-Phase-3-Launch-HTN-Trial-Demonstrating-Efficacy-and-Safety-of-Lorundrostat-in-Hypertension-Participants-with-High-Unmet-Medical.html

    GLOBENEWSWIRE
    05 Sep 2025
    Share Share
    Mineralys Therapeutics Announces Late-Breaking Data Presentation
    Mineralys Therapeutics Announces Late-Breaking Data Presentation

    24 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/24/3087776/0/en/Mineralys-Therapeutics-Announces-Late-Breaking-Presentation-of-Data-from-the-Launch-HTN-Pivotal-Trial-of-Lorundrostat-in-Uncontrolled-or-Resistant-Hypertension-at-34th-European-Mee.html

    GLOBENEWSWIRE
    24 May 2025
    Share Share
    Mineralys Therapeutics Announces Ph 2 Advance-HTN Results in NEJM
    Mineralys Therapeutics Announces Ph 2 Advance-HTN Results in NEJM

    23 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/23/3066971/0/en/Mineralys-Therapeutics-Announces-Publication-of-Pivotal-Phase-2-Advance-HTN-Results-in-the-New-England-Journal-of-Medicine-NEJM.html

    GLOBENEWSWIRE
    23 Apr 2025
    Share Share
    Mineralys Reports Late-Breaking Data From Advance-HTN Trial
    Mineralys Reports Late-Breaking Data From Advance-HTN Trial

    29 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/29/3051760/0/en/Mineralys-Therapeutics-Announces-Late-Breaking-Data-from-Advance-HTN-Pivotal-Trial-of-Lorundrostat-in-Uncontrolled-and-Resistant-Hypertension-Presented-at-the-American-College-of-C.html

    GLOBENEWSWIRE
    29 Mar 2025
    Share Share
    Mineralys Reports Positive Ph3 Lorundrostat Data In Hypertension
    Mineralys Reports Positive Ph3 Lorundrostat Data In Hypertension

    10 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/10/3039559/0/en/Mineralys-Therapeutics-Announces-Positive-Topline-Results-from-Launch-HTN-and-Advance-HTN-Pivotal-Trials-of-Lorundrostat-for-the-Treatment-of-Uncontrolled-or-Resistant-Hypertension.html

    GLOBENEWSWIRE
    10 Mar 2025
    Share Share
    Mineralys Completes Enrollment in Explore-CKD Ph 2 for Hypertension
    Mineralys Completes Enrollment in Explore-CKD Ph 2 for Hypertension

    04 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/04/3020225/0/en/Mineralys-Therapeutics-Completes-Enrollment-in-Explore-CKD-Phase-2-Trial-of-Lorundrostat-for-the-Treatment-of-Hypertension-in-Subjects-with-Stage-2-to-3b-CKD-and-Albuminuria.html

    GLOBENEWSWIRE
    04 Feb 2025
    Share Share